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The sodium/hydrogen exchanger 6 (NHE6) localizes to recycling endosomes, where it mediates 




 exchange. Mutations in the SLC9A6 gene encoding 
NHE6 cause severe X-linked mental retardation, epilepsy, autism and corticobasal degeneration 
in humans. Patients with SLC9A6 mutations exhibit skeletal malformations, and a previous study 
suggested a key role of NHE6 in osteoblast-mediated mineralization. The goal of this study was 
to explore the role of NHE6 in bone homeostasis. To this end, we studied the bone phenotype of 
NHE6 knock-out mice by microcomputed tomography, quantitative histomorphometry and 
complementary ex vivo and in vitro studies.  
We detected NHE6 transcript and protein in both differentiated osteoclasts and mineralizing 
osteoblasts. In vitro studies with osteoclasts and osteoblasts derived from NHE6 knock-out mice 
demonstrated normal osteoclast differentiation and osteoblast proliferation without an 
impairment in mineralization capacity. Microcomputed tomography and bone histomorphometry 
studies showed a significantly reduced bone volume and trabecular number as well as an 
increased trabecular space at lumbar vertebrae of 6 months old NHE6 knock-out mice. The bone 
degradation marker c-terminal telopeptides of type I collagen was unaltered in NHE6 knock-out 
mice. However, we observed a reduction of the bone formation marker procollagen type 1 N-
terminal propeptide, and increased circulating sclerostin levels in NHE6 knock-out mice. 
Subsequent studies revealed a significant upregulation of sclerostin transcript expression in both 
primary calvarial cultures and femora derived from NHE6 knock-out mice. 
Thus, loss of NHE6 in mice causes an increase of sclerostin expression associated with reduced 






























The endoskeleton of land vertebrates is mainly composed of hydroxyapatite (Ca5(PO4)3OH) [34]. 
Both synthesis and degradation of hydroxyapatite by osteoblasts and osteoclasts, respectively, 
are highly regulated, pH-dependent processes. Hydroxyapatite formation causes a massive 
release of H
+
 ions, in contrast, its dissolution requires acidification. Hence, not surprisingly, both 














exchangers (NHEs) [31]. Mineralizing osteoblasts exhibit high NHE activity [23]. While NHE1 
expression was observed along the entire plasma membrane, NHE6 seemed to be enriched at the 
basolateral surface of calcifying osteoblasts, indicating that NHE6 may play a role in the 
transcellular disposal of H
+ 
ions which are released during hydroxyapatite formation [23]. Two 
additional NHE isoforms, NHE3 and NHE4, have been detected in human bone-derived 
osteoblasts [25, 27]. The functional role of individual NHEs in osteoblasts, however, remains 
unknown at the moment. 
In bone degrading osteoclasts, transcellular H
+
 transport occurs in the opposite direction 
compared to osteoblasts [33]. H
+
 ions are secreted into the resorption lacuna at the bone surface 
by the V-ATPase at the apical membrane and HCO3
-




 exchanger isoform AE2 [40]. Both resorbing and non-resorbing osteoclasts also exhibit 
significant NHE activity, and non-selective NHE inhibition by amiloride or its derivatives seems 
to attenuate osteoclast differentiation and reduce adhesion of osteoclasts to mineralized surfaces 
[14-16, 20]. Osteoclasts were previously shown to express the two NHE isoforms NHE1 and 
NHA2 at the basolateral membrane [13, 18]. To our knowledge, rigorous in vitro and in vivo 
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in osteoblasts, the expression pattern of currently known NHE isoforms as well as the 
contribution of individual NHEs to osteoclast function remains unknown at the moment.  





 exchange and is essential for clathrin-mediated endocytosis, receptor recycling 
and endosomal signaling [26, 30, 42]. In a few specialized cells, it has a major plasmalemmal 
distribution, e.g. in cells of the inner ear where it is critical for normal hearing [17, 22], or as 
outlined above, in osteoblasts [23]. Receptor for activated C kinase 1 (RACK1)-dependent 
translocation of NHE6 from endosomes to the plasma membrane was recently shown to induce 
endosomal acidification, suggesting physiological regulation of endosomal pH by variation of 
endosomal NHE6 abundance [28, 29]. 
Nonsense and missense variants as well as deletions in the SLC9A6 gene encoding the NHE6 
isoform cause severe X-linked mental retardation, epilepsy, autism and corticobasal degeneration 
with tau deposition in affected males [7, 11, 12, 37]. Female carriers of pathogenic SLC9A6 
variants also exhibit neurocognitive deficits. To date, only little information is available about 
the consequences of pathogenic SLC9A6 gene variants in humans or of NHE6 gene disruption in 
mice outside the central nervous system. Christianson et al. reported skeletal malformations 
including long and narrow face, straight nose, square prognathic jaw, large ears and narrow chest 
in affected family members suggesting a possible role of NHE6 in bone turnover [7].  
Given the importance of endocytosis in both osteoclasts and osteoblasts, the previously 
suspected involvement of NHE6 in osteoblast-mediated bone formation and reports on skeletal 
malformations in patients with pathogenic SLC9A6 gene variants, we hypothesized that NHE6 










Schnyder D et al., Page 7 
 
 
i) explore the expression pattern of NHE isoforms in osteoblasts and osteoclasts and to ii) 
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MATERIAL AND  METHODS 
Unless specified otherwise, all chemicals and reagents were obtained from Sigma.  
  
Animal studies 
All animal experiments were in accordance with the Swiss Animal Welfare Law, approved by 
the Local Veterinary Authority Bern (Veterinäramt Bern; permits # 21/13 and 23/16) and 
complied with the ARRIVE guidelines. Mice had free access to water and standard chow diet 
(#3436 from Provimi Kliba AG, Kaiseraugst, Switzerland) and were maintained on a 12 hours 
light/12 hours dark cycle. Mice with a targeted Nhe6 gene disruption (Jackson Laboratories 
Stock# 005843, strain name B6.129P2-Slc9a65tm1Dgen) were obtained from Steven Walkley, 
Albert Einstein College of Medicine, Bronx, NY, USA. All mice were backcrossed for >10 
generations into a C57Bl6/J background.  
 
Micro-CT analysis 
Bone structure was determined in a µCT40 System (Scanco, Brüttisellen, Switzerland) as 
described [29]. Freshly excised bone specimens were fixed in 4% paraformaldehyde, rinsed 
overnight with tap water and immersed in 70% ethanol. MicroCT scans were performed in 70% 
ethanol at the highest resolution, with a voxel size of 6 µm [39]. 
 
Osteoclasts 
Primary osteoclasts were prepared from M-CSF dependent non-adherent osteoclast progenitor 
cells (OPCs) as described [12,28]. Briefly, femora and tibiae of 14-week-old mice were dissected 
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with 100 U/ml penicillin and 100 U/ml streptomycin. Cells were cultured overnight in α-MEM 
containing 10% heat inactivated FBS and 30 ng/ml M-CSF. Non adherent cells were then 
sedimented, resuspended, counted and plated at a density of 4 x 10
5
 cells per ml in α-MEM 
supplemented with 10% FBS in the presence of 30 ng/ml M-CSF (Chiron, Emeryville, CA) and 
20 ng/ml RANKL with medium changes every 3 days. Resorptive capacity of osteoclasts was 
assesses as described [29,40]. Solutions of 0.12 M Na2HPO4 and 0.2 M CaCl2 in 50 mM 
Tris/HCl pH 7.4 were preincubated overnight in a 5 % CO2 incubator at 37 °C. Equal volumes 
were mixed and a CaP slurry precipitated. After washing twice with water, the slurry was 
resuspended in 1 ml of water/90 μl slurry. To the CaP suspension, 
45
CaCl2 (PerkinElmer, 
Schwerzenbach, CH) was added to a specific activity of 1700 Bq/20 μg slurry. Of the spiked 
suspension, 200 μl was distributed into wells of 48-well plates, dried at room temperature for 3 
days, and baked at 80 °C for 3 h. Before use, the CaP-coated plates were equilibrated with 30 % 
FBS in cell culture medium over night. Osteoclasts were generated in cultures of OPC for 4 days 
with M-CSF (30 ng/ml) and RANKL (20 ng/ml) in 5-cm-diameter petri dishes (Avantor, Radnor 
PA, USA). Mature osteoclasts were detached from the dishes by adding PBS with 0.02% EDTA 
and incubating the plates at 37 °C. The cells from one petri dish were resuspended in 417 μl 
αMEM/FBS and 50 μl was distributed into the CaP-coated 48-well plates containing 200 μl 
αMEM/FBS/M-CSF/RANKL with 15mM HCl. After 24 h, the cell supernatants were collected 
and the solubilized 
45
Ca was counted in a scintillation counter. 
 
Osteoblasts 
Isolation of primary osteoblasts from calvaria of was performed as described [40]. Primary 
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old mice and digested for 5 × 20 min with 3 mg/ml collagenase type II (Worthington, NJ, USA) 
in HBSS. Fractions containing osteoblasts were pooled and 106 cells were seeded into 75-cm
2
 
culture flasks and in α-MEM supplemented with 10% FBS. After 4 days, cells were aliquoted to 
10
6
 cells per ml and frozen. Before experiments, cells were expanded in culture medium for 4 
days and subsequently plated to 4 x 10
4
 cells per ml. Induction with osteogenic induction 
medium, staining for alkaline phosphatase activity and quantification of mineralization nodules 
with Alizarin red S staining were performed as described in detail previously [41,42]. 
 
Osteoblast – osteoclast co-cultures 
Osteoclast formation in mouse co-cultures were essentially performed as described [30,40]. On 
day 0, 4 × 10
3
 osteoblasts and 4 × 10
4
 OPCs, isolated as described above, were seeded in 96 well 
plates, containing α-MEM supplemented with 10% FBS, 10 nM 1,25-(OH)2 vitamin D3 and 
recombinant murine TNFα (0.5 ng/ml; Genentech, San Francisco, USA). Medium was then 
changed every third day and osteoclast differentiation assessed at days 3 to 6 by measuring 
TRAP activity and counting of TRAP+ multinucleated cells (MNC; ≥ 3 nuclei/cell). 
 
Bone histomorphometry 
Fixed bones stored in 70 % ethanol were dehydrated with graded acetone and embedded in 
methyl methacrylate. Undecalcified frontal plane lumbar vertebra sections were cut at 4 µm 
thickness by microtome (RM2255, Leica, Germany). The first section was stained with Von 
Kossa to identify mineralized bone. The second section was stained with 2% Toluidine Blue (pH 
3.7) for the analysis of osteoblasts (Ob.S/BS, N.Ob/BS), and osteoid tissue (OS/BS, O.Th.). The 
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osteoclast numbers and surface (Oc.S/BS, N.Oc/BS). The sections were viewed with the Nikon 
E800 microscope equipped with an Olympus DP71 digital camera. Von Kossa image capture 
was performed using Olympus CellSens software under 2X magnification or otherwise specified 
by scale bar. The bone histomorphometric data was obtained at 20X magnification, in a 
normalized region of interest (ROI) located 200 µm away from the growth plate. The 
OsteoMeasure analyzing software (Osteometrics Inc., Decatur, GA, USA) was used to generate 
and calculate the data. The parameters are presented according to the standardized nomenclature 
[43]. 
 
RNA isolation, RT-PCR and quantitative real-time PCR 
RNA extraction from femora was performed as described [21]. RNA extraction of cultured cells, 
reverse transcription and realtime PCR using pre-synthesized Taqman®-based Assays-on-
Demand (Life Technologies/ABI, Rotkreuz, CH) were performed as described previously [29]. 
The following Assays-on-Demand were employed: Alkaline phosphatase (Mm00475831_m1), 
Osteocalcin (Mm03413826_mH), Osteoprotegerin (Mm00435454_m1), NHE6 
(Mm00555445_m1), Calcitonin receptor (Mm00432282_m1), Cathepsin K (Mm00484039_m1), 
Sclerostin (Mm00470479_m1), Osterix (Mm04933803_m1), Runx2 (Mm00501584_m1), 
CCAAT/ enhancer binding protein α (Mm00514283_s1), GAPDH (Mm99999915_g1). CT 
values for triplicate technical replicates were averaged and the amount of mRNA relative to 
GAPDH calculated using the ΔCt method. 
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Antibodies used in the study were from the following sources: monoclonal anti-transferrin 
receptor (Invitrogen, Waltham, MA, USA), monoclonal anti-early endosomal antigen 1 (BD 
Biosciences, Franklin Lakes, N.J., USA), monoclonal anti-GAPDH Mouse (Sigma-Aldrich, St. 
Louis, MO, USA). Generation and characterization of the rabbit ani-NHE6 antibody has been 
described [18,44]. Immunoblotting and quantification was performed as described [45]. 
 
Subcellular fractionation 
Subcellular fractionation was essentially performed as described [9, 18]. At day 4 of 
differentiation, osteoclasts derived from WT mice were lysed and the homogenate subjected to 
fractionation. Fractions were collected from top (#1) to bottom (#15) after centrifugation of cell 
homogenates (1 mg protein/gradient) on a linear sucrose gradient for 18 h at 200,000×g. 
Fractions were then analyzed by immunoblotting. 
 
Bone turnover markers, plasma electrolytes and renal function parameters 
Procollagen type 1 N-terminal propeptide (P1NP) in serum was quantified by P1NP EIA 
(Immunodiagnostic systems, Boldon, United Kingdom), C-terminal telopeptides of type I 
collagen (CTX) in serum was quantified by RatLaps™ (CTX-I) EIA (Immunodiagnostic 
systems), parathyroid hormone (PTH) in plasma was quantified by the Mouse Intact PTH 1-84 
Elisa kit (Quidel, San Diego, CA, USA),  sclerostin in serum was quantified by Mouse/Rat 
SOST/Sclerostin Quantikine ELISA Kit (# MSST00; R&D Systems, Minneapolis, MN, USA), c-
terminal and intact FGF-23 in plasma were measured by Mouse/Rat FGF-23 C-term ELISA kit 
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Clemente, CA, USA). Measurements of plasma electrolytes, creatinine and urea were done at the 
Central laboratory of the Bern University Hospital [46]. 
 
NHE transport activity 
NHE activity was measured fluorometrically using the intracellularly trapped pH-sensitive dye 
BCECF with the NH4Cl prepulse technique as described previously [35]. Cells grown on glass 
coverslips were loaded with 1 M BCECF-AM and exposed to 25 mM NH4Cl for 15 min in a 
buffer containing in mM: 120 NaCl, 5 KCl, 2 CaCl2, 1.5 MgCl2, 25 NH4Cl, 30 Hepes titrated to 
pH 7.4 with NMDG. Then, cells were washed 3x with and incubated in a buffer containing in 
mM: 120 Tetramethylammonium-Cl (TMACl), 5 KCl, 2 CaCl2, 1.5 MgCl2, 30 Hepes titrated to 
pH 7.4 with NMDG. Recording was started and after 60 s cells were rapidly exposed to a buffer 
containing in mM: 120 NaCl, 5 KCl, 2 CaCl2, 1.5 MgCl2, 30 Hepes titrated to pH 7.4 with 
NMDG. BCECF fluorescence signals ( excitation: 490 and 440 nm,  emission: 535 nm) were 
recorded in a computer-controlled spectrofluorometer (Fluoromax-2, Photon Technology 
International). The 490/440 nm fluorescence ratio was calibrated to pHi using the K
+
/nigericin 
method, and initial rate (Vmax; pH/time) of sodium-dependent intracellular pH recovery 
calculated. [35]. All steps of incubation, recording and calibration were performed at 37 °C. 
Comparisons were always made between cells studied on the same day. 
 
Statistical analysis 
For comparisons between groups the unpaired Student’s t test (two groups) or one-way ANOVA 
with Tukey post-hoc test (multiple groups) was used. Data were analyzed using GraphPad Prism 
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was considered statistically significant. Unless stated otherwise, data are shown as means and 















Spectrum of NHE isoform expression in osteoclasts and osteoblasts  
Currently, 13 NHE paralogs (SLC9 gene family) have been identified in mammalian genomes, 
encompassing nine SLC9A family members NHE1 – NHE9 (or SLC9A1-SLC9A, respectively), 
two SLC9B subfamily members NHA1 and NHA2 (or SLC9B1 and SLC9B2, respectively), and 
two SLC9C subfamily members SLC9C1 (or sperm NHE) and SLC9C2 [10]. SLC9C2 is a 
putative NHE for which no data currently exist. We analyzed the mRNA expression pattern of 12 
NHE isoforms (excluding SLC9C2) in mature murine osteoclast derived from macrophage 
colony-stimulating factor (M-CSF) dependent non-adherent osteoclast progenitor cells (OPCs) as 
well as in mineralizing murine osteoblasts derived from neonatal calvaria. As shown in Fig. 1A-
D, transcripts encoding most of the known NHE isoforms are expressed in both cell types. In 
osteoclasts, we were unable to detect transcripts of the epithelial NHE isoforms NHE3 and 
NHE4 and of the sperm NHE. Whereas NHE3 and sperm NHE mRNAs were also undetectable 
in mineralizing osteoblasts, NHE4 transcript was detectable in osteoblasts. As depicted in Fig. 
1A and B, treatment with RANKL led to a significant upregulation of several NHEs, including 
NHE2, NHE5, NHE7 and the two SLC9B subfamily members NHA1 and NHA2. In contrast, 
NHE9 was significantly downregulated by RANKL. In mineralizing osteoblasts, we observed 
upregulation of NHA1 and NHA2, and downregulation of NHE2 and NHE5, compared to 
osteoblasts not cultured in osteogenic induction medium containing -glycerophosphate (Fig. 
1C,D). In both differentiated osteoclasts and mineralizing osteoblasts, we detected high transcript 
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Role of NHE6 in osteoclasts 
As outlined earlier, the main goal of this study was to determine the role of NHE6 in bone 
homeostasis. We first set out to determine the role of NHE6 in osteoclast differentiation and 
function. To this end, NHE6 expression was assessed during RANKL-induced osteoclast 
differentiation in OPCs isolated from wild-type (WT) and NHE6 knock-out (KO). OPCs were 
cultured in the presence of 20 ng/ml RANKL and 30 ng/ml M-CSF for a total of 6 days. As 
shown in Fig 2A-C, NHE6 mRNA and protein increased in OPCs with RANKL treatment. No 
NHE6 mRNA (not shown) or protein (Fig. 2 B) were detectable in OPCs derived from NHE6 
KO mice. In subcellular fractionation experiments, NHE6 co-migrated with the transferrin 
receptor, a marker of recycling endosomes, as expected from previous studies in other cell types 
(Fig. 2D) [4, 26]. No relevant overlap of the NHE6 signal was detected with the early endosomal 
marker EEA1. To assess differentiation of WT and NHE6 KO osteoclasts, OPCs treated with 20 
ng/ml RANKL and 30 ng/ml M-CSF were harvested at days 3, 4, 5 and 6 of culture, and tartrate-
resistant acid phosphatase (TRAP) activity of cell lysates as well as the number of TRAP 
positive (TRAP
+
), multinucleated cells (MNC; ≥3 nuclei/cell) were quantified. As shown in Fig. 
3A-B, differentiation into mature osteoclasts was unaffected by loss of NHE6. Similarly, 
induction of osteoclast differentiation markers was not different between the two groups of OPCs 
(Fig. 3 D, E). We then examined the resorptive activity of mature osteoclasts in vitro, as 
described [1, 2, 41]. Osteoclasts were collected at day 4 of differentiation and seeded into 
calcium-phosphate (CaP) coated wells, containing 
45
Ca as a tracer. Resorptive activity was 
calculated as 
45
Ca released into the cell culture supernatant, normalized to TRAP activity 24 h 
after seeding. As shown in Fig. 3C, there was a small but significant decrease of the resorptive 
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Role of NHE6 in osteoblasts 
In a next series of experiments, we used primary osteoblasts to study NHE6 expression, 
proliferation and cell-mediated mineralization in vitro. To this end, osteoblasts were cultured in 
osteogenic induction medium containing -glycerophosphate [36]. As shown in Fig. 4A-C, 
NHE6 mRNA and protein were found to be expressed in osteoblast cultures throughout day 28. 
No NHE6 mRNA (not shown) or NHE6 protein (Fig. 4B, C) were detectable in osteoblasts 
derived from NHE6 KO mice. During culture, there was a time-dependent increase of NHE6 
mRNA expression (Fig. 4 A). On protein level, we detected an increase from day 7 to day 14 of 
culture, but in later culture stages, NHE6 protein expression levels returned to early culture 
levels (Fig. 4B, C).   
Throughout culture day 28, no differences in the expression of osteoblast differentiation markers 
(Fig. 5A, B), alkaline phosphatase activity (Fig. 5C, D) or viability (Fig. 5E) were apparent 
between WT and NHE6 KO osteoblasts. To assess the mineralization capacity, osteoblasts were 
cultured in osteogenic induction medium supplemented with 10 mM -glycerophosphate for 28 
days. Medium without -glycerophosphate served as negative control. Quantification of 
mineralization by Alizarin red was performed at days 7, 14, 21 and 28 (Fig. 5C, F). We observed 
significantly higher mineralization at days 21 and 28 days of culture in osteoblasts derived from 
NHE6 KO mice compared to osteoblasts derived from WT littermate mice.  
We next also conducted osteoblast-osteoclast co-cultures to study the role of NHE6 in 
osteoblast-osteoclast interactions. To this end, osteoblasts isolated from WT or NHE6 KO mice 
were co-cultured with OPCs either isolated from WT or NHE6 KO mice. Cells were harvested at 
days 3, 4, 5 and 6 of culture, and TRAP activity of cell lysates and the number of TRAP
+
, 
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osteoclasts in the co-culture system was not affected by deficiency of NHE6 in either osteoblasts, 
OPCs or both cell types. 
 
NHE transport activity in NHE6 KO osteoblasts 
Although NHE6 is an intracellular NHE involved in endosomal pH homeostasis [4], NHE6 was 
proposed to localize to the plasma membrane in osteoblasts and participate in cytosolic pH 
homeostasis [23]. We thus assessed plasmalemmal NHE transport activity in WT and NHE6 
osteoblasts. To this end, osteoblasts were maximally acidified using the NH4Cl pre-pulse 
technique and the sodium-dependent intracellular pH recovery quantified in the presence or 
absence of the NHE inhibitor amiloride (Fig. 7A, B) [35]. In both WT and NHE6 KO 
osteoblasts, amiloride completely abrogated NHE activity, suggesting that plasmalemmal NHE 
transport in WT and NHE6 KO osteoblasts is mediated by the amiloride-sensitive NHE isoform 
NHE1 [24], which is highly expressed in both mineralizing and non-mineralizing osteoblasts 
(Fig. 1 B). Furthermore, NHE transport activity was similar between non-mineralizing and 
mineralizing WT and NHE6 KO osteoblasts, indicating that NHE6 has no role in cytoplasmatic 
pH regulation in osteoblasts. 
 
Structural bone parameters assessed by microcomputed tomography in NHE6 KO mice 
To determine the impact of the in vitro findings observed with osteoblasts and osteoclasts 
derived from NHE6 KO mice on structural bone parameters, we performed high-resolution 
microcomputed tomography (micro-CT) studies on lumbar vertebrae of 3 months old male WT 
and NHE6 KO mice. As depicted in Fig. 8A-D, with the exception of a lower bone volume 
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differences in structural bone parameters between the two groups of mice. Based on these 
findings, we decided to further age cohorts of WT and NHE6 KO mice. As shown in Figure 8, at 
6 months of age, both male (E-H) and female (I-L) NHE6 KO mice displayed a significantly 
reduced BV/TV and trabecular number as well as an increased trabecular space at all three 
lumbar vertebral sites studied (L3, L4 and L5). Mean body weight was similar between the two 
groups of mice at 6 months of age (31.5 g  ± 1.8 g WT males and 32.5 g ± 1.4 g NHE6 KO 
males, p = 0.588; 24.1 g ± 1.8 g WT females and 27.3 g  ± 2.9 g NHE6 KO females, p = 0.156). 
 
Bone histomorphometry  
To further investigate the bone phenotype of NHE6 KO mice, we next performed bone 
histomorphometry of lumbar vertebrae in 6 months old WT and NHE6 KO mice (Tables 1, 2). 
Structural histomorphometry parameters in female NHE6 KO mice confirmed a significant 
decrease in trabecular bone volume and trabecular numbers with a corresponding increase in 
trabecular spacing, but no change in trabecular thickness, consistent with osteopenia. These 
parameters were not significantly modified in NHE6 KO males, albeit a clear trend to decreased 
BV/TV was observed. When testing the results by two way ANOVA to distinguish the gender 
effects from the effects of NHE6 KO independently and their interaction (Table 2), NHE6 KO 
mice exhibited a significant decrease in trabecular bone volume and trabecular numbers with a 
corresponding increase in trabecular spacing, and no significant change in trabecular thickness 
compared to WT mice. Despite the expected differences between genders, no significant 
interaction between gender and genotype was detected, confirming that the effects of NHE6 KO 
were similar in males and females. In contrast to structural parameters, cellular 
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reveal any significant differences between WT and NHE6 KO mice, suggesting that the cellular 
changes that led to low bone mass occurred at earlier time points, as indicated by the decrease in 
bone formation marker procollagen type 1 N-terminal propeptide (P1NP) we observed at 3 
months of age (Fig. 9A). 
 
Circulating mineral metabolism markers and gene expression in bone of WT and NHE6 KO mice 
We next quantified in 3 months old mice circulating levels of the bone formation marker 
procollagen type 1 N-terminal propeptide (P1NP) and of the bone degradation marker C-terminal 
telopeptides of type I collagen (CTX). Serum P1NP levels were significantly lower in NHE6 
mice compared to WT mice (Fig. 9A), while CTX levels were similar in both groups of mice 
(Fig. 9B), suggesting attenuated bone formation as the mechanism for reduced bone volume in 
NHE6 KO mice. To further investigate the cause of reduced bone formation in NHE6 KO mice, 
we measured plasma parathyroid hormone (PTH), intact and C-terminal fibroblast growth factor 
23 (FGF-23), plasma electrolytes and renal function parameters in WT and NHE6 KO mice. As 
shown in Fig. 9 C-E and Table 3, these studies did not reveal differences between the two groups 
of mice. However, sclerostin, a bone-derived glycoprotein with anti-anabolic effects on 
osteoblasts [3, 5, 39], was significantly elevated in NHE6 KO mice compared to WT mice (Fig. 
9 F). We next assessed sclerostin transcript expression in primary calvarial cultures derived from 
WT and NHE6 KO mice in vitro. As demonstrated in Fig. 9 G, sclerostin transcript expression 
was significantly upregulated in NHE6 KO cells. To assess sclerostin expression in vivo, we 
isolated RNA of femora from 3 months old WT and NHE6 KO mice, and quantified sclerostin 
and canonical Wnt pathway target gene transcript expression (Figs. 9 H-K). Results obtained 
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circulating sclerostin levels observed in NHE6 KO mice. In addition, we observed upregulation 
of the osteogenic inducers Runx2 and Osterix in NHE6 KO mice, while no difference was 
observed between WT and NHE6 KO mice in the expression of the adipogenic inducer 
CCAAT/enhancer binding protein α [19]. 
Together, these data suggest that NHE6 KO mice exhibit a cell-autonomous increase of 














Our expression analysis reveals that most known NHE isoforms are expressed in the two main 
cell types of bone, osteoblasts and osteoclasts. Of the plasmalemmal clade (including isoforms 
NHE1-NHE5), NHE1, NHE2 and NHE5 are the main paralogs expressed. Both NHE2 and 
NHE5 exhibit differential regulation in the two cell types, being upregulated by RANKL and 
downregulated in mineralizing osteoblasts. In contrast, all paralogs of the intracellular clade 
NHE6-NHE9 are abundantly expressed in both cell types. Changes observed were an 
upregulation of NHE7 and a pronounced ~10x fold downregulation of NHE9 upon RANKL 
stimulation. Interestingly, both SLC9B subfamily paralogs were not only significantly 
upregulated in osteoclasts, as reported previously [6, 18], but also in mineralizing osteoblasts. 
Together, these results lay the ground for the exploration of the physiological relevance of 
individual NHEs in bone biology.  
In this study, we focused on the intracellular NHE isoform NHE6. Micro-CT studies of bones 
isolated from WT and NHE6 KO mice revealed an age-dependent reduction in bone volume of 
NHE6 KO mice. Alterations in structural bone parameters were confirmed by histomorphometry, 
and the two-way ANOVA analysis revealed a highly significant effect of NHE6 deletion on bone 
volume, independent of gender. Although bone volume was lower at 6 months of age, we 
detected no alterations in cellular histomorphometry parameters in NHE6 KO mice. The 
reduction of the bone formation marker P1NP in 3 months old NHE6 KO mice indicates that the 
cellular changes responsible for the significantly reduced bone volume observed in 6 months old 
NHE6 KO mice occur at an earlier time point. A limitation of this study is the absence of 
fluorescent labels in bone and dynamic assessment of the rates of mineralization and bone 
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mechanism, dynamic histomorphometry data will be needed to quantify bone turnover and 
mineralization. 
Experiments performed with primary bone cells derived from WT and NHE6 KO mice revealed 
subtle differences. The resorptive capacity of NHE6 KO osteoclasts was decreased. In contrast, 
osteoclast differentiation assessed by exogenous addition of RANKL to OPCs or in the 
osteoblast-osteoclast co-culture assay was not affected by loss of NHE6. The basis of the 
resorptive deficit in NHE6 KO osteoclasts remains unknown at the moment. Vesicular transport 
along the endo-lysosomal pathway, however, is critical for polarization of osteoclasts and the 
development of the ruffled border, the resorptive organelle of the osteoclast [8]. Hence it is 
possible that polarization, development of the ruffled border and/or endosomal signaling are 
impaired in NHE6-deficient osteoclasts. 
Surprisingly, our in vitro studies did not reveal an impairment in osteoblast function, as expected 
[23]. In contrast, our data indicate that proliferation of NHE6-deficient osteoblasts is normal and 
mineralization increased in vitro. The mechanisms responsible for increased mineralization of 
NHE6-deficient osteoblasts are currently unknown and may be due to alterations in endosomal 
pH with subsequent changes in endosomal trafficking or signaling. Our studies also indicate that 
NHE6 is dispensable for cytoplasmic pH regulation in osteoblasts. However, constitutive global 
KO of NHE6 may result in compensatory changes which mitigate or mask a phenotype. Future 
studies will need to employ cell-specific and inducible KO models of NHE6 to investigate this 
further. 
The finding of decreased resorptive activity of osteoclasts and increased mineralization of 
osteoblasts upon loss of NHE6 in vitro is difficult to reconcile with the in vivo data 
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volume in NHE6 KO mice. Our data reveal that there is a cell autonomous increase of sclerostin 
expression in bone associated with elevated circulating sclerostin levels in NHE6 KO mice. 
Hence, an increase in sclerostin maybe responsible for the bone phenotype observed in NHE6 
KO mice. Sclerostin is an osteocyte-derived glycoprotein that functions as antagonist of the 
canonical Wnt pathway and thereby has anti-anabolic effects on osteoblasts. Surprisingly, our 
data reveal an increased expression of the osteogenic inducers Runx2 and Osterix in NHE6 KO 
mice [19]. Upregulation of Runx2 and Osterix may represent a counterregulatory response to 
elevated sclerostin levels. Alternatively, Runx2 and Osterix may be responsible for the 
upregulation of sclerostin expression in NHE6 KO mice. Recent data indicate that both Runx2 
and Osterix are important inducers of sclerostin expression in bone [32]. The reason for the cell-
autonomous increase of sclerostin expression in the bone of NHE6 KO mice remains unclear at 
the moment, and a limitation of our study is the lack of cellular histomorphometry data on 
osteocytes. We speculate that endosomal signaling (and hence outside-in signaling) may be 
altered upon loss of NHE6, resulting in augmented sclerostin mRNA transcription. However, 
other scenarios are also possible. Thus, both the molecular mechanisms of increased sclerostin 
expression and the contribution of sclerostin to the bone phenotype observed in NHE6 KO mice 
remain unclear and further studies are needed to obtain definitive answers.  
Our results also have implications for patients with pathogenic SLC9A6 gene variants or 
deletions. Low bone mass is associated with increased fracture risk, morbidity and mortality 
[38]. Certainly, data obtained in rodents cannot be directly extrapolated to humans. However, we 
believe that our results warrant investigations on bone density, bone turnover markers and 
sclerostin levels in patients with SLC9A6 -associated disease. Results of such studies may lay the 
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Female, WT  
(n=5) 
Female, KO  
(n=5) 
Male, WT  
(n=5) 
Male, KO  
(n=5) 
BV/TV (%)  16.47±2.45 11.44±3.15 * 17.81±3.42 14.60±1.70 
Tb.Th (µm)  45.32±2.00 42.14±4.60 42.56±6.51 38.00±2.08 
Tb.N (/mm)  3.64±0.51 2.68±0.55 * 4.17±0.40 3.84±0.30 ## 
Tb.Sp (µm)  234.84±45.84 346.57±98.71 * 199.23±27.43 224.02±22.68 # 
Ob.S/B.Pm (%) 20.36±5.18 17.98±8.10 10.96±2.00 13.34±3.59 
N.Ob/B.Pm (#/mm) 13.52±2.79 12.49±6.39 7.33±1.15 9.59±2.20 
OS/BS (%)  9.88±4.21 8.59±6.19 5.24±1.58 7.50±3.10 
O.Th (µm)  2.28±0.26 2.61±0.52 2.27±0.45 2.23±0.50 
Oc.S/B.Pm (%) 11.17±2.32 11.60±1.44 8.67±1.63 8.91±2.36 
N.Oc/B.Pm (#/mm)  5.65±0.76 6.76±1.55 4.33±0.80 4.48±1.00 # 
Bone volume/total volume fraction (BV/TV), trabecular number (Tb.N.), trabecular thickness 
(Tb.Th.), trabecular space (Tb.Sp.), osteoblast number/bone perimeter (N.Ob/B.Pm), osteoclast  
number/bone perimeter (N.Oc/B.Pm), osteoblast surface/bone surface (Ob.S/BS), osteoclast  
surface/bone surface (Oc.S/BS), osteoid thickness (O.Th), osteoid surface/bone surface (OS/BS). 
*, p<0.05 statistically significant vs. female, WT (Tukey post-hoc test). 
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Female vs Male WT vs KO 
Interaction between 
gender and genotype 
BV/TV (%) P=0.0872 p=0.0041 p=0.4691 
Tb.Th (µm) p=0.0876 p=0.0583 p=0.7195 
Tb. N (mm) P=0.0007 p=0.0055 p=0.1381 
Tb. Sp (µm) P=0.0071 p=0.0169 p=0.1089 
Ob.S/B.Pm (%) p=0.0085 p=0.9990 p=0.3231 
N.Ob/B.Pm (#/mm)  p=0.0144 p=0.7144 p=0.3369 
OS/BS (%)  p=0.1401 p=0.7953 p=0.3495 
O.Th (µm)  p=0.3433 p=0.4643 p=0.3696 
Oc.S/B.Pm (%)  p=0.0097 p=0.7113 p=0.9114 
N.Oc/B.Pm (#/mm)  p=0.0018 p=0.2094 p=0.3333 
Bone volume/total volume fraction (BV/TV), trabecular number (Tb.N.), trabecular thickness 
(Tb.Th.), trabecular space (Tb.Sp.), osteoblast number/bone perimeter (N.Ob/B.Pm), osteoclast  
number/bone perimeter (N.Oc/B.Pm), osteoblast surface/bone surface (Ob.S/BS), osteoclast  
surface/bone surface (Oc.S/BS), osteoid thickness (O.Th), osteoid surface/bone surface  
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Table 3. Blood parameters of WT and NHE6 KO mice 
Plasma parameter 
(concentration) 
WT NHE6 KO p-value 
Na (mM) 147.25±1.03 147.25±1.83 NS 
K (mM) 5.22±0.46 5.8±0.91 NS 
Cl (mM) 98.25±1.28 99.5±2.07 NS 
Ca (mM) 2.24±0.06 2.26±0.06 NS 
P (mM) 2.62±0.32 2.91±0.56 NS 
Mg (mM) 0.96±0.07 1.02±0.13 NS 
Creatinine (µM) 9.75±1.67 11.5±1.77 NS 
Urea (mM) 8.95±1.36 7.72±1.20 NS 
 
Na = sodium, K = potassium, Cl = chloride, Ca = calcium, P = inorganic phosphate, Mg = 
magnesium. N = 8 male mice per genotype, 3 months old. Results shown are mean ± SD. 
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FIGURE  LEGENDS 
 
Figure 1. Expression of NHE isoforms osteoclasts and osteoblasts. A, B) Osteoclasts: Primary 
M-CSF dependent non-adherent osteoclast progenitor cells (OPCs) were cultured with or without 
RANKL for 4 days. B) Controls for RANKL dependent osteoclast development. C, D) 
Osteoblasts: primary osteoblasts isolated from calvaria of 1 – 2 days old mice were cultured for 
28 days with (osteogenic medium) or without 10 mM –glycerophosphate (–GP). D) Controls 
for osteogenic induction. The abundance of target mRNA relative to GAPDH mRNA was 
calculated using the ΔCt method. Values are shown as means ±SD; * p <0.05, ** p<0.01, *** 
p<0.001. 
 
Figure 2. Expression of NHE6 during osteoclast differentiation. Primary M-CSF dependent non-
adherent osteoclast progenitor cells (OPCs) were cultured in the presence of 20 ng/ml RANKL 
and 30 ng/ml M-CSF for up to 6 days. A) NHE6 transcript expression during osteoclast 
differentiation. At day 3 to day 6 of differentiation, cells were lysed, mRNA isolated and target 
gene expression quantified by real-time PCR analysis using Taqman probes. No NHE6 transcript 
was detectable in osteoclasts from NHE6 KO mice (not shown). The abundance of NHE6 
mRNA relative to GAPDH mRNA was calculated using the ΔCt method. Values are shown as 
means ±SD; * p <0.05 and ** p<0.01 compared to day 3. 
B, C) NHE6 protein expression during osteoclast differentiation in osteoclasts derived from WT 
and NHE6 KO mice. At day 3 to day 6 of differentiation, cell lysates were prepared and equal 
amounts of protein (50 µg) were separated by SDS-PAGE and probed with indicated antibodies. 
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in osteoclasts derived from NHE6 KO mice. C) Quantification of immunoblots of three 
independent experiments. NHE6 protein expression relative to GAPDH, normalized to day 3 
vehicle treatment.  Values are shown as means ±SD; * p <0.05 and ** p<0.01 compared to day 
3. D) Localization of NHE6 in osteoclasts assessed by subcellular fractionation. EEA1: Early 
endosomal antigen; TFR: Transferrin receptor. Equal volumes of each fraction were loaded per 
lane. Experiment shown is representative of 3 individual experiments. 
 
Figure 3. In vitro characterization of osteoclast differentiation and function. Primary M-CSF 
dependent non-adherent OPCs isolated from WT and NHE6 KO
 
mice were cultured in the 
presence of 20 ng/ml RANKL and 30 ng/ml M-CSF for up to 6 days. A) TRAP activity 
normalized to XTT in OPC cultures harvested at indicated days. B) Quantification of TRAP
+
 
multinucleated cells (MNC; ≥ 3 nuclei/cell) at indicated days. C) Resorptive activity of 
osteoclasts at day 4 of RANKL stimulation, quantified as 
45
Ca released in the supernatant 
normalized to TRAP activity. D,E) Transcript expression of osteoclast differentiation markers 
relative to GAPDH, calculated using the ΔCt method. Values are shown as means ±SD; * p 
<0.05. 
 
Figure 4. Expression of NHE6 in osteoblasts. Primary osteoblasts isolated from calvaria of 
newborn WT or NHE6 KO mice were cultured up to 28 days in osteogenic induction medium 
containing 10 mM -GP. A) NHE6 transcript expression. At days 7, 14, 21 and 28 of culture, 
osteoblasts were lysed, mRNA isolated and target gene expression quantified by real-time PCR 
analysis using Taqman probes. No NHE6 transcript was detectable in osteoblasts from NHE6 
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ΔCt method. B, C) NHE6 protein expression during osteoblast proliferation in osteoblasts 
derived from WT and NHE6 KO mice. At days 7, 14, 21 and 28 of culture, cell lysates were 
prepared and equal amounts of protein (50 µg) were separated by SDS-PAGE and probed with 
indicated antibodies. No NHE6 protein was detected in osteoclasts derive from NHE6 KO mice. 
B) Representative immunoblot. C) Quantification of immunoblots. NHE6 protein expression 
relative to GAPDH. Values are shown as means ±SD; * p <0.05 compared to day 3. 
 
Figure 5. Expression of osteoblast differentiation markers, alkaline phosphatase activity and 
mineralization. Primary osteoblasts isolated from calvaria of newborn WT or NHE6 KO mice 
were cultured up to 28 days in the presence of 10 mM -GP (osteogenic induction medium). A-
B) Alkaline phosphatase and osteocalcin transcript expression. At days 7, 14, 21 and 28 of 
culture, osteoblasts were lysed, mRNA isolated and target gene expression quantified by real-
time PCR analysis using Taqman probes. The abundance of target mRNA relative to GAPDH 
mRNA was calculated using the ΔCt method. C) Representative images of alkaline phosphatase 
(left panels) and Alizarin red staining (right panels) in osteoblast cultures at days 7, 14, 21 and 
28. D) Quantification of alkaline phosphatase activity in osteoblast cultures at days 7, 14, 21 and 
28. E) Assessment of cell viability of osteoblast cultures at days 7, 14, 21 and 28 by XTT assay. 
F) Quantification of Alizarin red staining in osteoblast cultures by acetic acid extraction and 
colorimetric detection at 405 nm at days 7, 14, 21 and 28. Values are shown as means ±SD; **** 
p <0.0001. 
 
Figure 6. In vitro osteoclast differentiation in osteoblast-osteoclast co-cultures. Primary OPCs 
isolated from WT and NHE6 KO
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of newborn WT or NHE6 KO mice for up to 6 days. A) TRAP activity normalized to XTT in 
OPC cultures harvested at indicated days. B) Quantification of TRAP
+
 multinucleated cells 
(MNC; ≥ 3 nuclei/cell) at indicated days. Values are shown as means ±SD. 
 
Figure 7. NHE transport activity in osteoblasts. Measurement of plasma membrane NHE 
transport activity in non-mineralizing (A) and mineralizing (B) osteoblasts by quantification of 
the sodium-dependent intracellular pH recovery after acidification of the cytoplasma, in the 
presence or absence of the NHE inhibitor amiloride (1 mM). Values are shown as means ±SD. 
 
Figure 8. Structural bone parameters of WT and NHE6 KO mice at 3 and 6 months of age. 
Lumbar vertebrae (# 3, 4 and 5) at 3 or 6 month of age were isolated and analyzed by μCT. A-D) 
Histograms representing structural parameters of lumbar vertebrae of 3 months old male mice. E-
H) Histograms representing structural parameters of lumbar vertebrae of 6 months old male 
mice. I-L) Histograms representing structural parameters of lumbar vertebrae of 6 months old 
female mice.Total volume / bone volume fraction (BV/TV), trabecular number (Tb.N.), 
trabecular thickness (Tb.Th.), trabecular space (Tb.Sp.). Values are shown as means ±SD; * p 
<0.05, ** p <0.01, *** p<0.001. 
 
Figure 9. Circulating mineral metabolism markers and gene expression in bone of WT and 
NHE6 KO mice at 3 months of age. A) Serum procollagen type 1 n-terminal propeptide (P1NP), 
B) Serum C-terminal telopeptides of type I collagen (CTX), C) Plasma parathyroid hormone 
(PTH), D) Plasma Intact fibroblast growth factor 23 (Intact FGF-23), E) plasma C-terminal 
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expression in primary calvarial cultures, H-K) Sclerostin, Osterix, Runx2 and CCAAT/enhancer 
binding protein α (CEBPA) transcript expression in femora of 3 months old mice. The 
abundance of target mRNA relative to GAPDH mRNA was calculated using the ΔCt method. 























































































































































 Mutations in the sodium/hydrogen exchanger 6 (NHE6) cause mendelian disease 
 A previous study suggested a key role of NHE6 in osteoblast function 
 In vitro proliferation and mineralization capacity is normal in NHE6 KO osteoblasts 
 NHE6 KO mice exhibit low bone volume with a reduced bone formation marker P1NP 
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